The outpatient use of atypical antipsychotics with Alzheimer's disease.
Farver
Debra
D
South Dakota State University College of Pharmacy, USA.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000401:mortality; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D015337:Multicenter Studies as Topic; D000077152:Olanzapine; D010045:Outpatients; D010919:Placebos; D000069348:Quetiapine Fumarate; D018570:Risk Assessment; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D018492:Dopamine Antagonists; D010919:Placebos; D012702:Serotonin Antagonists; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine